Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Astellas Initiates Patient Enrollment in PII Trial of Tivozanib for Triple Negative Breast Cancer
December 5, 2012
- US Merck Initiates Multinational PII/III Study for BACE Inhibitor for Alzheimer’s Disease
December 5, 2012
- Pediatric NDA for AcipHex Granted Priority Review by US FDA: Eisai
December 4, 2012
- Hospira Applies for Irinotecan Generic for Pediatric Malignant Solid Tumors Based on Data from the Public Domain
December 4, 2012
- Novartis Concludes Comarketing Agreement with Taisho for SGLT-2 Inhibitor Luseogliflozin
December 4, 2012
- Sanwa Kagaku, Kowa Launch DPP-4 Inhibitor Suiny on November 30
December 3, 2012
- Novartis AG Receives First Approval for Cell-Culture Influenza Vaccine in the US
December 3, 2012
- Fast-growing Plavix Could Become Japan’s No. 1 Ethical Drug by Next Year
December 3, 2012
- US FDA Accepts NDA Filing for Tivozanib: Astellas
November 30, 2012
- CMIC MPSS to Offer Comprehensive Region-Wide CSO Service for Long-Listed Drugs
November 30, 2012
- China’s Drug Costs to Expand to 11 Trillion Yen in 2030 by 5% Annual Growth: UtoBrain
November 29, 2012
- Long-Listed Products to Be Switched to Combination Drugs, Original Drugs Rather than Generics: President Sawai
November 29, 2012
- Sawai to Seek Alternative Suppliers for All of Its Products
November 29, 2012
- Santen Files Anti-Allergic Ophthalmic Solution DE-114
November 29, 2012
- Chugai, Nippon Shinyaku Conclude Codevelopment, Comarketing Agreement for Anti-CD20 Antibody
November 29, 2012
- Takeda to Establish Medical Affairs Department within Development Division
November 28, 2012
- Approximately 30% of Doctors Conduct ALK Gene Test in All Patients: Pfizer Survey
November 28, 2012
- Pfizer Launches Glycylcycline Antibiotic Tygacil
November 27, 2012
- 8 Companies’ Entries to COPD Market Turn It into Red Ocean
November 27, 2012
- Bayer Eyes Sales of €3 Billion in Japan by 2017: Chairman Dekkers
November 27, 2012
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…